Cefotaxime therapy in children with serious infections associated with reduced host defense mechanisms

Thirty children were treated with cefotaxime (CTAX) in this study. The children suffered from respiratory tract infection (4), skin and soft tissue infection (4), infection of bones or joints (2), gastrointestinal infection (5), septicaemia (5), septicaemia and urinary tract infection (3), septicaemia and infection of the skin (3), septicaemia and infection of bones (2), urinary tract infection and infection of bones (1), enterocolitis (1). Nine out of these patients had leukaemia and 2 bone marrow aplasia. The dose of CTAX usually was 100 mg/kg/day. There were 25 cures and 4 failures and in one case assessment was impossible. Local tolerance of intravenous injection was good and no serious side-effects were reported